Intravenous immunoglobulin induced pancytopenia while preventing development of gestational alloimmune liver disease: A case report.
Case Rep Womens Health
; 35: e00422, 2022 Jul.
Article
em En
| MEDLINE
| ID: mdl-35646608
ABSTRACT
Gestational alloimmune liver disease is a rare complication associated with reactive maternal immunoglobulins resulting in neonatal liver pathology. The mainstay treatment for prevention in future pregnancies is intravenous immunoglobulins. Although relatively well tolerated, adverse reactions may occur. In this report, we highlight a case of intravenous immunoglobulin induced pancytopenia diagnosed by exclusion after thorough work-up. The patient was counseled on options and an informed decision was made to proceed with re-trial of intravenous immunoglobulin without systemic prednisone. This resulted in the delivery of a healthy neonate. We propose that future adverse reactions to intravenous immunoglobulin in pregnancy may warrant the trial of a new medication lot and use of systemic steroids only if subsequently indicated.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Case Rep Womens Health
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos